| Similar Articles |
|---|
 |
Chemistry World
July 2010 |
Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors   |
Chemistry World
December 2009 |
Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs |
Chemistry World
October 14, 2008
Simon Hadlington |
Enzymes hit with double punch US chemists have made a small molecule that simultaneously blocks two key enzymes involved in the growth of cancer cells. |
Managed Care
May 2004
Thomas Morrow |
New Agents Regulating Tyrosine Kinase Can Be Used Against Several Cancers When traditional therapies fail in cancer treatment, turning off a chemical switch may offer hope to the hopeless. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
Chemistry World
September 2009 |
Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit. |
The Motley Fool
September 11, 2008
Brian Orelli |
Glaxo's Not Gambling The pharmaceutical's deal for drug developer Cellzome is back-end loaded. |
Chemistry World
January 7, 2014
Derek Lowe |
Is there a drug for that? One hears a lot about the concept of 'druggability' in pharmaceutical research. If that concept has any meaning (and it probably does), then the implication is that there must be such a thing as 'undruggability'. So what does that look like? |
Chemistry World
July 3, 2015
Andy Extance |
Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry. |
Chemistry World
June 23, 2015
Derek Lowe |
Missing the target There are enzymes that no mustard has ever cut, to steal a phrase from science fiction author James Blish. Phosphatases, the flip side of kinase activity, are a perfect example. |
Chemistry World
October 28, 2011
Laura Howes |
Clicking Your Way to Synthetic Antibody Therapies Scientists have clicked together synthetic antibodies using the enzymes they want to target as a template. These synthetic antibodies can then be used to bind to the enzyme templates they were cast from, which could open up a whole new field of therapeutic molecules. |
Pharmaceutical Executive
December 1, 2008
Ron Feemster |
The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond. |
Pharmaceutical Executive
December 1, 2005
Ron Feemster |
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Bio-IT World
August 13, 2002
Kevin Davies |
Curtailing the Cancerous Cell The highly touted drug Gleevec unleashed new hope in the battle against cancer. Now a group of new drugs, working on the same principle, are showing even greater promise in treating leukemia. |
Chemistry World
December 2008 |
Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project. |
The Motley Fool
June 5, 2008
Brian Lawler |
Cancer Concerns Fuel FDA Inquiry The agency examines a class of blockbuster drugs for a link to cancer in young patients. |
Chemistry World
February 3, 2006
Simon Hadlington |
High Throughput Screening for Kinase Inhibitors Researchers have developed a system for assessing the activity of a crucial class of enzymes involved in cellular signalling pathways. |
The Motley Fool
June 22, 2004
Charly Travers |
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline. |
The Motley Fool
July 18, 2005
Karl Thiel |
Stocks That Make You Breathe Easier Allergies and asthma are big markets that several firms aim to tackle. Investors, take note. |
Bio-IT World
February 10, 2003
Malorye Branca |
The Art of the Deal Vertex Pharmaceuticals CEO Joshua Boger speaks about deal making and his company's success. |
The Motley Fool
June 25, 2010
Brian Orelli |
Diversification Times 50,000 Gilead Sciences diversifies any way it can. |
Chemistry World
February 24, 2015
Phillip Broadwith |
B-MS bolsters immuno-oncology with pair of deals In a bid to bolster its pipeline of immuno-oncology drugs, Bristol-Myers Squibb has agreed to buy US biotech firm Flexus Biosciences in a deal worth up to $1.25 billion |
Bio-IT World
February 10, 2003
Malorye Branca |
Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic. |
The Motley Fool
February 22, 2011
Luke Timmerman |
Gilead Buys Calistoga Pharma, Making Move Into Cancer Drugs Gilead diversifies with Calistoga purchase. |
Chemistry World
July 2, 2013
Derek Lowe |
Target acquired Phenotypic screening has recently seen a revival in popularity. This technique assesses drug candidates first by their effects in some organism, then works back to their causes. It can be an effective strategy, but when you find some interesting results, the need to explain them can become acute. |
Managed Care
November 2004
Thomas Morrow |
Pharmacogenetic, Pharmacogenomic Testing Rapidly Gaining Acceptance New tests will allow better determination of which therapies will work on which patients, thus improving care and reducing outlays for failed therapies. |
Pharmaceutical Executive
November 1, 2012 |
Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes. |
Chemistry World
December 20, 2012
Andrew Turley |
Gilead buys YM for $510m US pharma company Gilead is to buy YM BioSciences, a drug discovery firm based in Ontario, Canada, for $510 million. |
Bio-IT World
July 14, 2004 |
The True Cost of Drug Discovery A new book with the provocative title "The $800 Million Pill" threatens to "strip away pharmaceutical industry spin" about the true cost of drug development. |
Bio-IT World
February 2006 |
News Blast Hit-to-Lead... Whole Genome... Gleevec Resistance... |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
BusinessWeek
October 4, 2004 |
"It's a Perfect Storm" for Drugmakers Glaxo CEO Jean-Pierre Garnier answers questions about the biotech industry's hardships and how his company is improving its search for new drugs |
The Motley Fool
September 21, 2007
Brian Orelli |
Size Does Matter BioCryst announces failed phase 2 data with an excuse, and plans phase 3 before year-end. Investors, take note. |
Chemistry World
August 2, 2013
Phillip Broadwith |
India revokes more pharma patents India's Intellectual Property Appellate Board has revoked one of two patents granted to GlaxoSmithKline for its cancer drug lapatinib. |
